Less Recurrence Seen With Endoscopic Submucosal Dissection of Large Lesions
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Dec. 11, 2023 -- For patients with large benign colonic lesions, endoscopic submucosal dissection (ESD) is associated with reduced recurrence at six months compared with endoscopic mucosal resection (EMR), according to a study published online Dec. 12 in the Annals of Internal Medicine.
Jérémie Jacques, M.D., Ph.D., from Service d'Hepato-Gastro-Enterologie in Limoges, France, and colleagues compared ESD and EMR for large colonic adenomas in a multicenter study involving six French referral centers. Patients with large (≥25 mm) benign colonic lesions referred for resection were randomly assigned to ESD or EMR (178 and 182 patients, respectively). The primary end point was six-month local recurrence.
The researchers found that in the primary analysis set, which included 318 lesions in 318 patients, recurrence occurred after 0.6 and 5.1 percent of 161 ESDs and 157 EMRs, respectively (relative risk, 0.12). After ESD, there were no recurrences observed in R0-resected cases. There were more adverse events after ESD than EMR (35.6 versus 24.5 percent; relative risk, 1.4).
"Patients and physicians should be aware of these study results not only to know when to choose endoscopic resection instead of surgery but also to choose the endoscopic resection strategy that best fits the patient according to the lesion, the acceptance of follow-up colonoscopy, and the available expertise at the center," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-12-12 22:15
Read more
- Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
- Want to Slowly Cut Down on Dietary Salt? Here's How
- FDA Appoints New Head of Medical Devices
- Substantial Mortality Benefits Expected From Optimal Medication Use for HFrEF
- ASH: Complications Common With Controlled Ovarian Hyperstimulation in Sickle Cell Anemia
- Prenatal Cannabis Exposure May Impact Executive Function, Behavior at Age 5 Years
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions